Charles Rudin
Affiliations: | University of Chicago, Chicago, IL |
Area:
Molecular BiologyGoogle:
"Charles Rudin"Parents
Sign in to add mentorUrsula Storb | grad student | 1986-1991 | Chicago |
Craig B. Thompson | post-doc | (Chemistry Tree) |
Children
Sign in to add traineeRobyn S. Karnauskas | grad student | 2004 | Chicago |
David J. VanderWeele | grad student | 2005 | Chicago |
Jennifer L. Brace | grad student | 2006 | Chicago |
Christy R. Hagan | grad student | 2006 | Chicago |
John Thomas Poirier | grad student | 2006-2012 | Johns Hopkins Medical School |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Rudin CM, Liu SV, Soo RA, et al. (2023) SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301363 |
Li Z, Zhuang X, Pan CH, et al. (2023) Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Cancer Discovery |
Zavitsanou AM, Pillai R, Hao Y, et al. (2023) KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell Reports. 42: 113295 |
Li Z, Zhuang X, Pan CH, et al. (2023) Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Biorxiv : the Preprint Server For Biology |
Elkrief A, Riccuiti B, Alessi JV, et al. (2023) Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. The Oncologist |
Gentzler RD, Villaruz LC, Rhee JC, et al. (2023) Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. The Oncologist |
Pillai R, LeBoeuf SE, Hao Y, et al. (2023) Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in mutant lung cancer. Biorxiv : the Preprint Server For Biology |
Chakraborty S, Coleman C, Manoj P, et al. (2023) De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Rudin CM, Reck M, Johnson ML, et al. (2023) Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. Journal of Hematology & Oncology. 16: 66 |
Rudin CM, Balli D, Lai WV, et al. (2023) Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |